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Amino acid and albumin losses during hemodialysis. Protein and
calorie malnutrition are prevalent in chronic hemodialysis (HD) patients
and has been linked to increased mortality and morbidity in this patient
population. Concern has been raised that the open pore structure of high
flux membranes may induce the loss of more amino acids (AA) compared
to low flux membranes. To address this issue, we prospectively analyzed
pre- and post-HD plasma AA profiles with three different membranes in
nine patients. Simultaneously, we measured dialysate AA losses during
HD. The membranes studied were: cellulosic (cuprophane-CU), low flux
polymethylmethacrylate (LF-PMMA), and high flux polysulfone (HF-PS)
during their first use. Our results show that pre-HD plasma AA profiles
were abnormal compared to controls and decreased significantly during
HD with all dialyzers. The use of HF-PS membranes resulted in signifi-
cantly more AA losses into the dialysate when compared to LF-PMMA
membranes (mean so; 8.0 2.8 g/dialysis for HF-PS, 6.1 1.5 g/dialysis
for LF-PMMA, p <0.05, and 7.2 2.6gldialysis for CU membranes, P =
NS). When adjusted for surface area and blood flow, AA losses were not
different between any of the dialyzers, We also measured dialysate AA
losses during the sixth reuse of the HF-PS membrane. Losses of total AA
increased by 50% during the sixth reuse of HF-PS membrane compared to
its first use. In addition, albumin was detected in the dialysate during the
sixth reuse of HF-PS membrane. We therefore measured albumin losses in
all patients dialyzed with HF-PS membranes as a function of reuse.
Albumin losses increased significantly beyond 15 reuses. Average albumin
losses were 1.5 1.3 gldialysis below the 15th reuse, but increased to 9.3
5.5 g/dialysis during the 20th reuse. We conclude that the abnormal
plasma AA profile in HD patients is further exacerbated with hemodialysis
for most of the individual amino acids, and that dialysate AA losses are
modulated by membrane characteristics and reuse. Further, HF-PS mem-
branes with reuse numbers over 15 lose substantial amounts of albumin in
the dialysate.
branes have been shown to increase protein catabolism [19, 20].
Gutierrez et al have reported the increased breakdown of skeletal
muscle protein during sham dialysis with bioincompatible cellulo-
sic membranes in healthy subjects [21]. This effect was not seen
during sham dialysis with biocompatible membranes.
Losses of amino acids during hemodialysis may also contribute
to malnutrition [22, 23]. Although amino acid losses during
dialysis have been reported previously, these studies have been
performed using conventional cellulosic membranes [24—26].
Losses with membranes with higher pore sizes, the so called
high-flux membranes, have not been published [22]. In addition,
the effect of biocompatibility and the effect of reuse of these
membranes on losses of amino acids have not been reported
previously. Such studies are important with the increasing preva-
lence of reuse, which is estimated to be practiced in more than
80% of dialysis units, particularly in dialysis units using high-flux
membranes. The reprocessing of such membranes for reuse may
potentially affect their pore sizes and change the magnitude or
distribution of amino acid losses in the dialysate.
In this study, we measured the impact of three different
hemodialysis membranes on plasma amino acid concentrations
and simultaneously measured the amino acid losses in the dialy-
sate with same membranes. We also assessed the effect of reuse
on these variables in high flux dialyzers.
Methods
Patient characteristics
Protein and calorie malnutrition are estimated to be present in
approximately 20% of patients on dialysis [1—3]. There is increas-
ing evidence linking poor nutritional status to increased mortality
and morbidity in this patient population [4—6], Several factors
have been identified which may contribute to this problem.
Among these are anorexia and decreased nutrient intake [7, 8],
hormonal derangements, such as insulin resistance, increased
glucagon sensitivity and excess parathyroid hormone levels
[9—12], intake of multiple medications [131, metabolic acidosis
[14, 15], and frequent hospitalizations [16].
Dialysis-related factors may also have an important impact on
malnutrition [17, 18]. Hemodialysis with certain types of mem-
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Nine male patients participated in the study which was con-
ducted at the Veterans Administration Medical Center (VAMC)
in Nashville. The mean age of the patients was 61 10.8 years and
the mean time on hemodialysis was 29 14.9 months. Three of
the patients were insulin-dependent diabetics. All patients were
dialyzed with high flux polysulfone membranes prior to entering
the study. Urea kinetic modelling and protein catabolic rates
(PCR) of the patients were calculated every three months (Miste-
bar® Computer Cons., Woodridge, Illinois, USA). The KTIV and
PCR results of the nine patients participating in the study were
1.49 0.09 and 0.95 0.11 g/kgfday, respectively, and they had a
mean serum albumin level of 3.71 0.30 g/dl. All patients had a
small meal approximately one hour prior to each dialysis treat-
ment which was similar in composition. The average food com-
position of their meal was 15.2 6.8 grams of protein and 365
162 calories.
Membrane characteristics
The characteristics of the membranes used in the study are
shown in Table 1. The low flux cellulosic (CU) membrane and the
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Table 1. Membrane characteristics of the study dialyzers
Membrane
Cuprophane
(CU)
Polymethylmethacrylate
(PMMA)
Polysulfone
(PS)
Manufacturer Terumo T150 Toray B2 1.5H Fresenius F80
Surface area m2 1.5 1.5 1.8
Pore size distr. (A) 15—35 15—20 60—80
UFR ml/hr/mm Hg 5.1 5 55
Qb mI/mm 300 300 400
Qd mI/mm 500 500 500
Abbreviations are: Qb, blood flow, Od, dialysate flow.
low flux polymethylmethaciylate (PMMA) membrane had similar
surface areas of 1.5 square meters (m2), whereas the high flux
polysulfone (PS) membrane had a surface area of 1.8 m2. The CU
membrane used in this study had a pore size ranging between 15
and 35 angstroms (A) which is higher than the conventional
cuprophane membranes. The PMMA membrane had a pore size
between 15 to 20 A while PS had a pore size ranging from 60 to
80 A.
Clinical Protocol
All patients were dialyzed consecutively with each of the three
study dialyzers during the same week. All hemodialysis proce-
dures were performed with a volumetric control device (Fresenius
2008 E). Blood flow rates were 300 mI/mm for the low flux CU and
PMMA membranes and 400 mI/mm for high flux PS. Dialysate
flow rates were 500 mI/mm for all treatments and dialysis time was
240 minutes per session. The dialysate used during the study was
identical for all treatments and contained sodium (139 mEq/liter),
potassium (2 or 3 mEq/liter according to the patient's needs),
calcium (2.5 mEq/liter), and bicarbonate (39 mEqlliter).
The dialysis unit has been practicing reuse for the past 10 years
using an automated reuse machine (Seratronics DRS 4), with
bleach and formaldehyde. The concentration of the bleach in
contact with the dialyzer was 0.27%. The contact time of the
dialyzer with the bleach was five minutes for the PS membranes.
Formaldehyde exposure was for 2.5 minutes at a final dilution of
1.5%. Dialyzers were incubated in 1.5% formaldehyde for at least
24 hours at 38°C.
Plasma amino acids
Plasma amino acid concentrations were measured during the
first use of all three study dialyzers. Measured parameters in-
cluded; pre- and post-dialysis (15 mm following termination of
dialysis) blood samples from arterial blood lines for amino acid
(AA) profiles and blood chemistries at each dialysis sessions. For
comparison, control plasma samples were obtained from six
healthy individuals, both fasting and one hour following ingestion
of breakfast containing approximately 15 grams of protein.
Plasma samples were separated from blood within 15 minutes of
collection and all specimens were stored at temperatures —20°C
immediately, until specific assays were performed.
Dialysate amino acid losses
Dialysate amino acid losses were initially measured during the
first use of all three study dialyzers, and subsequently, during the
sixth reuse of PS membrane. We did not carry out measurements
of the other two membranes beyond their first use, Blood flow,
ultrafiltration rate (and surface area) were similar during the first
and sixth use of this dialyzer. Mean ultrafiltration rate for these
patients was 665 87.5 mi/hr.
The volumetric dialysis machines (Fresenius 2008 E) were
specially equipped with a dialysate sampling port which allowed
continuous collection of efferent dialysate fluid throughout dialy-
sis at a constant rate identical in volume to the total volume of
ultrafiltrate, Typical collection volumes were 2 to 3 liters per
dialysis session. Aliquots of dialysate were stored at —20°C.
Assays
Blood chemistries (BUN, creatinine, glucose, sodium, potas-
sium, chloride, and total C02) were performed using standard
laboratory techniques. Plasma and dialysate amino acid profiles
were measured by reverse-phase high pressure liquid chromatog-
raphy (HPLC) using a modified version of the methods of
Bidiingmeyer, Cohen and Tarvin [27] and Heinrikson and
Meredith [281 in which amino acids are derivatized with phenyl-
isothiocyanate. The phenylthiocarbamoyl amino acids are sepa-
rated over a 65 minute gradient and detected at 254 nm. Glu-
tamine concentrations were determined enzymatically [29].
Microalbumin was detected in dialysate samples collected
during the sixth reuse of high flux PS. We therefore collected
dialysate aliquots from additional patients during their subse-
quent clinical dialysis using the high flux PS membrane. Mi-
croalbumin assays were done using Beckmann Array Analyzer
with specific immunoprecipitation method.
Statistical analysis
Repeated measures analysis of variance was used to assess
overall differences between the three types of membranes studied.
When these were statistically significant, we used paired t-tests to
assess differences between pairs of membranes; in the absence of
a significant overall effect, these were considered artifacts of the
repeated significance tests. Paired t-tests were also used to assess
changes within a group when only two measurements were being
considered (such as, effect of dialysis on plasma amino profiles
with a single membrane, or differences in effect with reuse of a
membrane.) Unpaired t-tests were used to compare results be-
tween groups (such as, between the control and the pre-dialysis
group).
Possible correlations between the pre-dialysis concentrations of
amino acids, their concentrations in the dialysate and their
clearances were assessed using a random effects model (with the
subject as random factor) and after adjusting for the molecular
weight of the amino acid and the membrane used. Standard
(Pearson) correlations are also reported.
Results
Blood chemistries
Pre-dialysis serum concentrations of BUN, creatinine, sodium,
potassium, chloride, and tCO2 were not different between patients
for any of the dialyzers. Of note, pre-dialysis tCO2 levels (23 4
mmol/liter) were in the normal range (23 to 30 mmollliter) in our
study patients and increased to 27 4 mmol/liter post-dialysis.
Hemodialysis treatment resulted in the expected changes in
routine blood chemistries and there were no significant differ-
ences in post-hemodialysis levels between the three membranes.
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Table 2. Pre- and post-dialysis plasma amino acid levels with different dialyzers and controls (.tmol/liter; N = 9)
Membrane
Amino acid Controls
CU PMMA PS
Pre PostPre Post Pre Post
1Mhistidinea 6.3 10.5 19 20 9 11" 19 18 15 25 20 30 9 14
3Mhistidinea 2.2 0.9 27 14 10 7b 30 15 13 10" 29 14 10 6
Alaninea 643.0 112.2 288 101 231 68 228 115 192 61 230 97 169 66
Arginine
Asparaginea
Aspartate
Citrullinea
117.1 17.2
114.1 49.7
5.2±1.5
36.2 18.4
97 36
58 21
4.0±2.1
115 47
78 22L'
52 12
2.3±0.9"
59 21"
95 41
59 19
3.7±0.9
113 42
67 22
50 14
2.0±0.7"
53 15"
103 32
61 20
4.7±3.9
111 46
65 23a
48 flab
1.9±0.8a
48 19
Glutamatea 21.2 7.5 142 53 100 43" 138 41 89 51" 134 46 94 53
Glycine
Glutamine
296.3 95.6
526.8 65
257 103
495 38
215 67
427 38b
245 66
484 63
190 80"
378 37"
261 127
525 93
205 86
366 56
Histidine 89.3 46.0 56 15 44 9" 58 20 47 15 60 18 41 12'
Hydroxyprolinea
Isoleucine
14.4 4.5
55.3 20.0
34 15
61 15
20 9b
60 16
34 23
68 15
16 11"52 2lc 31 2075 21 18 1155 2l'
Leucjne 113.3 30.8 100 22 103 24 110 27 92 33 125 32 92 29ab
Lysine 124.7 46.0 139 45 114 32" 146 46 110 40 155 48 107 36w'
Methionine 27.9 6.6 26 10 22 6 27 16 21 8 27 11 20 8
Ornithinea 40.8 10.1 61 22 37 14b 67 11 40 13" 66 19 37 ii
Phenylalaninea
Prolinea
45.8 9.8
485.8 122,9
61 13
297 150
63 7
230 103"
63 17
276 98
58 12
202 80"
68 16
284 116
55 l0'
190 87
Serinea 159.2 44.7 75 16 63 13b 75 22 52 26" 78 27 59 20
Taunnea 76.0 13.3 53 24 34 12" 41 16 30 12b 45 21 36 27
Threoninea 163.5 64.0 96 38 80 26" 103 47 77 31" 109 54 78 37'
Tryptophana
Tyrosinea
57.1 12.1
44.1 16.4
22 8
38 15
25 6
36 10
21 7
37 17
22 7
32 12
22 10
42 15
23 8
31
Valine 186.1 64.2 179 48 138 34" 196 51 135 47b 201 56 128 43aI
Totala 3452 332 2797 598 2252 448b 2737 514 2034 457b 2864 687 1982 53l"
BCAA 354.8 114.5 340 83 301 72 375 88 279 100" 400 102 274 91ab
Ess 980.2 259.8 836 204 727 152" 888 215 679 206" 944 239 662 204ai
NonEssa 2472 292 1960 415 1525 312" 1849 308 1354 274b 1921 468 1320 334
Values are given as mean SD.
a Control and average Pre-dialysis groups significantly different; P < 0.05.
"P < 0.05 vs. Pre.
P < 0.05 vs. CU-Post.
Plasma amino acid profiles
The concentration of individual amino acids as well as the
concentration of groups of amino acids (essential, non-essential,
and branched chain) in plasma before and after dialysis for each
of the membrane, and with non-fasting controls are shown in
Table 2. Pre-hemodialysis plasma amino acid levels were not
significantly different between the three dialysis groups for any
individual amino acid, or for any of the groups of amino acids.
However, compared to normal non-fasting controls, pre-dialysis
plasma amino acid levels showed notable difference. Specifically,
plasma levels of threonine, tryptophan, alanine, proline, serine,
asparagine, and taurine were significantly reduced, while plasma
levels of phenylalanine, glutamate, citrulline, ornithine, and meth-
ylated histidines were significantly elevated compared to non-
fasting controls (P < 0.05). When grouped together, total and
non-essential amino acid concentrations were also significantly
lower than the non-fasting controls (P < 0.01 for total and
non-essential amino acids).
Table 3 shows the change in individual amino acids, as well as
groups of amino acids during hemodialysis with each membrane.
For each of the membrane, the reduction in plasma amino acid
levels for essential (P < 0.05 in each membrane), non-essential
(P < 0.001 in each membrane) and total amino acids (P < 0.001
in each membrane) were statistically signilicant (Fig. 1). Of note
is that the decrease in BCAA levels were statistically significant
for PMMA and PS membranes (P < 0.01), but not for CU
membranes and the magnitude of the decrease in total, branched-
chain, and essential amino acid levels were significantly higher for
the PS membrane compared to CU membrane (P < 0.05).
Figure 2 (A and B) shows the pre- and post-hemodialysis
plasma levels versus controls for the essential and non-essential
amino acids, respectively. As can be seen, the majority of the
individual amino acid concentrations were low pre-dialysis (com-
pared to controls), and their concentrations were further reduced
with dialytic therapy. Plasma concentrations of a few individual
amino acids, such as methylated histidines, citrulline, hydroxypro-
line and glutamate, which were higher than the controls pre-
dialysis were normalized during hemodialysis.
Dialysate amino acid losses
Amino acid losses in the dialysate for all three membranes are
shown in Table 4. Total amino acid losses as well as essential and
non-essential groups were significantly higher with the high flux
PS in comparison to low flux PMMA (8.0 2.8 gldialysis vs.
6.1 1.5 g/dialysis, P < 0.05). Although more amino acids were
lost with CU membrane (7.1 2.6 g/dialysis) in comparison to
PMMA membrane, this difference was statistically significant only
for non-essential amino acids.
When the results were normalized for the surface area of
dialyzers, the losses for CU, PMMA, and PS were 4.8 1.7, 4.1
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Table 3. Effect of different dialysis membranes on difference of post to
pre-HD plasma amino acid concentrations (,amol/liter; N 9)
Amino acid cua PMMA PS
iMethyihistidine —9.2 9.4° —3.6 10.6 —11.0 15.7
3Methylhistidine —17.8 7.8c —17.3 6.0° —19.5 8.7°
Alanine —56.4 84.4 —36.3 97.4 —60.7 82.3
Arginine"
Asparagine
—18.8 19.3°
—6.6 10.4
—28.4 38.6
—8.7 15.8
—38.9 23.2"'
—13.8 13.3"'
Aspartate —1.7 1.9° —1.7 1.1° —2.8 3.8
Citrulline 55•9 30.3° —59.8 43.80 —63.0 335°
Glutamine —67.7 31.8° —106 69.40 —159 115.7°
Glutamate —41.8 35.6c —48.5 43.7° 39.4 38.6c
Glycine
Histidine
—41.8 57.1
—12.0 10.1°
—54.4 56.50
—10.8 18.6
—56.3 64.7°
—19.7 11.0°"
Hydroxyproline
Isoleucine"
—14.3 7.5°
—0.8 11.3
—17.7 21.10
—16.2 15.40t
—13.6 10.40
—19.4 213"'
Leucin&' 3.1 16.5 —18.3 27.0 —33.0 38.6°"
Lysine" —24.6 27.00 —36.1 48.1 —48.1 350cd
Methionine —3.5 6.6 —5.8 13.2 —7.0 6.90
Ornithine —23.2 17.1' —27.5 10.20 —28.4 11.80
Phenylalanineb 1.8 10.2 —5.5 13.1 —13.0 15.00
Proline —66.2 71.90 —74.6 67.50 —94.0 90.10
Serine —12.1 7•40 —22.4 20.10 —19.6 13.10
Taurine —19.1 18.1° —10.9 13.30 —8.4 23.6
Threonine —15.4 19.80 —26.5 30.30 —30.1 24.6°"
Tryptophan 2.7 3.8 0.8 3.7 1.2 5.7
Tyrosinet' —1.8 8.0 —5.0 12.1 —11.4 12.30
Valine —41.1 33.5' —61.7 32.80 —73.4 505"'
Total" —544 288,50 —703 43540 —882 508.4"'
BCAAb —38.9 54.4 —96.1 71.00 —126 104.10
Essentlalb —109 125.50 —209 216.7' —281 194.5"'
Non-essential —436 179.80 —495 271.30 —601 334.3'
Values are given as mean so.
a Negative values indicate decrements of concentrations at the end of
dialysis.bChange with dialysis significantly different between the three groups
(repeated measures analysis of variance, P < 0.05).
C Change with dialysis significantly different from zero (paired (-test, P <
0.05).
"Change with dialysis significantly different from change in cuprophane
group (paired f-test, P < 0.05).
1.0, and 4.4 1.6 grams/dialysis session, respectively. These
values were not statistically different from each other (P> 0.2 for
repeated measures analysis of variance; P> 0.4 for comparison of
PS membrane with PMMA membrane). In addition, since the
blood flow used for PS dialysis was 400 mI/mm, resulting in higher
(approximately 15%) clearances for small molecules, the losses
with the PS membrane, normalized for both surface area and
blood flow, was not statistically different from the other mem-
branes.
Amino acid lost in the dialysate was significantly associated with
the pre-dialysis concentration in plasma (P < 0.001) after adjust-
ment for molecular weight and subject, as described earlier. For
each membrane, there was a slight negative association between
molecular weight and clearance rate (r value ranging from —0.14
to —0.24, P < 0.05 in each membrane) and a strong negative
association between molecular weight and dialysate amino acid
losses (r value ranging from —0.36 to —0.45, P < 0.0001 for each
membrane).
Effect of reuse on high flux PS
Amino acid losses. With the sixth reuse of PS, total amino acid
losses increased to 12.2 4.4 grams per dialysis session (Table 4).
Although this represented a 50% increase in amino acid losses, it
did not reach statistical significance (P = 0.065), because of the
wide variations in individual values. This increase in total amino
acid losses was predominantly due (but not limited) to a statisti-
cally significant increase in losses of non-essential amino acids.
Specifically, 18 amino acids (Table 4) showed increased losses
during the sixth reuse of PS in comparison to the first use of PS
membrane (P < 0.05, sign test, two-sided).
Albumin losses. After detecting microalbumin in several dialy-
sate samples taken during the sixth reuse of PS membrane in our
initial study population, we collected dialysate aliquots from all
patients during their clinical dialysis with reused high flux PS
membranes. However, no further blood specimens were collected
during these procedures.
Albumin losses in the dialysate increased steadily with increas-
ing reuse number. The average concentrations of albumin in the
dialysate for ranges of reuse numbers are shown in Figure 3. As
can be seen, below the 10th reuse (N = 21), the quantity of
albumin lost is 0.98 0.91 grams per dialysis session (range 0 to
18 grams), increasing to 1.94 1.54 grams (range 0.3 to 8.6
grams) for dialyzers with 10 to 14 reuses (N = 33). The average
loss of albumin for dialyzers with 15 to 19 reuses (N = 36) was 4.3
3.29 grams (range 0.5 to 9.4 g), 9.28 5.50 g/treatment (range
1.1 to 20.8 g) for dialyzers with 20 to 24 reuses (N = 24) and 10.78
7.87 g/treatment (range 1.1 to 25.6 g) for dialyzers with over 24
reuses (N = 11), a sixfold increase over albumin losses before the
15th reuse.
Discussion
Multiple factors may contribute to the abnormal amino acid
profile seen in chronic renal failure [9]. These include inadequate
nutritional intake [19], uremic disturbances in amino acid metab-
olism [30], loss or fibrosis of renal tissue [31], metabolic acidosis
[14] and hormonal derangements [32]. Some of these factors, such
as metabolic acidosis, are partially corrected with dialytic therapy,
but others, such as decreased intake or hormonal disturbances,
may persist or worsen after initiation of dialysis. Decreased,
metabolically active, renal tissue is potentially another cause of
specific abnormalities seen in pre-dialysis plasma amino acid
profiles [31]. Increases in phenylalanine and citrulline and de-
creases in arginine and serine levels, as seen in our patients, have
been attributed to reduction of their renal metabolism resulting
from a decrease in metabolically active renal tissue [9]. On the
other hand, decreased plasma levels of several essential amino
acids such as histidine, threonine, and tryptophan observed in our
patient population, which were generally 30 to 40% less than the
normal controls, may reflect decreased food intake of these amino
acids. The differences in amino acid profiles between normal
controls and dialysis patients are even more pronounced for many
specific amino acids when compared to post-hemodialysis plasma
levels (Fig. 2A for essential and Fig. 2B for non-essential amino
acids).
Increased attention has been paid to the plasma levels of
leucine, isoleucine, and valine, the so-called branched-chain
amino acids (BCAA) because of their importance in skeletal
muscle energy metabolism, and because leucine has been shown
to enhance protein synthesis in vitro [33]. Although plasma BCAA
levels have been reported previously to be lower in chronic renal
failure patients [34], pre-dialysis BCAA levels in our study were
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Fig. 1. Decrease (Post-Pre) in plasma branched
chain (BCAA), essential (ESSAA), non-essential
(Non-ESSAA) and total (TotalAA) amino acid
levels during hemodialysis with different
membranes. Symbols are: (U) CU; (l) PMMA-
LF; (0) PS-HF, All changes are statistically
significant (P < 0.05), except BCAA during CU
dialysis. The magnitude of change with PS-HF
is significantly higher in comparison to CU for
total, branched chain, and essential amino acids
(P < 0.05).
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Fig. 2. (A). Pre-hemodialysis (0), post-
hemodialysis (0), and non-fasting healthy control
(U) concentrations of individual plasma essential
amino acids. (B). Pre-hemodialysis (0), post-
hemodialysis (0), and non-fasting healthy
control (U) concentrations of individual plasma
non-essential amino acids.
within the normal range. This is possibly due to the normalization
of metabolic acidosis in our patient population since metabolic
acidosis has been implicated in increased degradation of these
amino acids [35J.
Hemodialysis resulted in a significant decrease in plasma levels
of individual and total plasma amino acid levels with each of the
three membranes used. However, this reduction of the plasma
amino acid pool does not account for the total amino acid losses
(in the dialysate) during hemodialysis. Assuming an average
weight of 75 kg, a volume of distribution of 0.25 liter/kg, an
average intradialytic change of 750 mol/liter, and an average
molecular weight of 170 gIj.tmol, the decrease in the plasma pool
of amino acids accounts for less than 20% (1.5 to 2.2 g) of the total
loss in the dialysate. This discrepancy suggests an enhanced
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Table 4. Amino acid losses in the dialysate with different dialyzers
(mol/liter; N = 9)
PS-6th
Amino acid CU PMMA PS-lst use reuse
1-Methylhistidine
3-Methylhistidine
Alanine
1.7 1.2
2.1 1.449 24
1.0 0.9
1.3 1.4
32 13
1.7 1.9
2.1 1.1
44 24
NM
NM
84 48
Arginine
Asparágine
Aspartate
Citrulline
16 7"11 7
1.0 0.3"
11 5"
12 5
7.7 4.2
0.6 0.2
8.0 5.0
18 8
12 6"
0.8 0.511 8
22 17
27 lie
4.6 2.7c12 9
Glutamate 25 iO" 18 4 27 ii" 23 23
Glycine
Glutamine
Histidine
49 30
70 10
7.2 3.6
39 18
82 12
6.4 2.7
53 33
82 12
9.6 43""
84 58
92 49
13.2 6.2
Hydroxyproline
Isoleucine
4.1 2.212 6 3.2 1.611 4 4.6 3.216 7" 9.8 7.515 9
Leucine 21 8 19 7 27 9" 34 12
Lysine
Methionine
20 10
4.7 3.9"
19 7
2.6 2.4
27 13"
4.3 3.1
18 1222 l4
Ornithine 7.8 3.9 8.2 3.1 10.4 4.7" 7.6 4.1
Phenylalanine
Proline
12 6
52 26"
10 5
38 16
14 5"
52 27
12 6
156 54C
Serine 19 17 14 9 19 12" 44 50
Taurine 9.0 4.4 7.3 3.3 8.9 3.4 37 20C
Threonine 13 11 6.8 5.9 15 14" 18 11
Tryptophan
Tyrosine
Valine
3.2 1.4
6.8 3.9
31 15
2.6 0.9
5.2 3.0
27 11
3.2 1.1
7.9 34a
36 16"
7.3 2.7c
9.6 4.0
52 12
Total 457 178 382 102 504 190" 804 302
BCAA 63 28 57 22 79 32" 102 29
Essential 139 62 117 42 169 73" 214 65
Non-essential 318 118" 265 63 335 120" 590 246C
Total gldialysis 7.2 2.6 6.1 1.5 8.0 2.8 12.2 4.4
Values are given as mean SD.
C P < 0.05 vs. PMMA.
bp < 0.05 vs. CU.
cp < 0.05 vs. PS 1st use.
appearance of new amino acids during dialysis, most likely from
other tissue stores such as in skeletal muscle [36, 37].
Our study also revealed that hemodialysis with high flux PS
membrane results in more amino acid losses per dialysis session
(8.0 2.8 g) in comparison to hemodialysis with low flux PMMA
membrane (6.1 1.5 g), but not in comparison to CU membrane
(7.2 2.6 g). Wolfson, Jones and Kopple have earlier reported
amino acid losses of 8.2 grams per dialysis session, using conven-
tional cellulosic membranes [261, a value comparable to our
results. Our study extends this finding to high flux membranes
with larger pore sizes; although, as discussed earlier, these losses
may not be intrinsic to this membrane, but more related to the
larger surface area and higher blood flows used in clinical dialysis
with the PS membranes, nevertheless, the amino acid losses
during conventional clinical dialysis with such membranes are
substantially higher.
A notable feature of the plasma amino acid concentrations
during dialysis was the fact that there was no significant decrease
in intradialytic plasma BCAA levels with CU dialysis, in contrast
to PMMA and PS dialysis. Since losses of BCAA to the dialysate
were similar between these two different types of membranes, the
lack of significant intradialytic change in plasma BCAA levels with
CU suggests an increased appearance of BCAA during dialysis
with cellulosic membrane. This suggestion is further supported by
the observation that the change in plasma levels of total amino
acids was significantly less with CU membrane than PS mem-
brane, in spite of the similar losses to the dialysate. As was
previously demonstrated in healthy subjects during sham dialysis
[21], the complement activating properties of cellulosic mem-
branes [381, may be a potential explanation for this increased
release of amino acids in patients dialyzed with CU membranes.
Losses of amino acids in the dialysate were further exacerbated
when the high flux PS membrane was reused. Our results show
that at the sixth reuse of high flux PS, an average of 12.2 4.4
grams of total amino acids are lost to the dialysate during each
dialysis session, a 50% increase over the value seen during the first
use. Increased diffusive and convective losses of amino acids due
to increased porosity of the membranes are likely as chemicals
used for reprocessing the dialyzer, specifically bleach, tend to
enlarge their pores. Indeed, another clinically important evidence
of increased pore size with increasing reuse is the detection of
albumin in the dialysate during the sixth reuse of PS which was not
present during the first use of the same membranes. Thus after the
sixth reuse, albumin is detected in the dialysate during almost
every dialysis session. Although the losses are small before 15
reuses, averaging 1.5 grams per dialysis session, after the 15th
reuse, albumin losses increase exponentially and average up to 10
grams at the 25th reuse. These findings are consistent with recent
published results from Diaz et al [39] and Graeber et al [401, who
reported increased clearance of 132-microglobulin and increased
protein losses with increasing reuses of high flux membranes.
Using polydisperse dextran, preliminary studies of reused polysul-
fone dialyzers indicate the presence of larger pore sizes in the
reused dialyzers compared to new dialyzers (Unpublished data).
This chronic loss of albumin may result in decreased serum
albumin concentrations and possible changes in lipid profiles in
these patients. Moreover, these albumin losses may counteract the
possible beneficial nutritional effect of higher doses of dialysis
[41], and provide an explanation for the results of a recent report
which suggested that serum albumin levels in chronic hemodial-
ysis patients are not improved with increasing dialysis doses [42].
Since the dialysis dose is often increased by changing patients to
high flux dialyzers [43], albumin losses at high reuse numbers with
these dialyzers may counteract the expected increase in plasma
albumin levels. Indeed, after discontinuing reuse of HF-PS mem-
branes beyond 15, the concentration of serum albumin in the
patients increased by an average of 0.22 0.19 g/dl over three
months.
In conclusion, our results reveal that hemodialysis patients
display several abnormalities in plasma amino acid profiles.
Specifically, most of the essential amino acid levels are decreased
while some of the non-essential amino acid levels are increased.
Although the etiology of these abnormalities is likely to be
multifactorial [15, 44, 45], our findings suggest that the hemodi-
alysis membrane itself has a major impact on these observations
either by increasing catabolism and/or from losses into the
dialysate. In addition, high flux PS membrane allows more amino
acid losses compared to the low flux PMMA membrane. With the
sixth reuse of the PS, amino acid losses increase 50%. More
importantly, increased number of reuses of the high flux PS
membrane leads to leakage of albumin into the dialysate. After
the 15th reuse, a mean of 6.8 grams of albumin is lost per dialysis
procedure.
The clinical consequences and importance of this increased
amino acid losses and the adverse effect of reuse procedure on
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amino acid and albumin losses with high flux PS membranes need
to be more clearly defined by long term clinical studies. Although
the total loss of 6 to 8 grams of amino acids per dialysis session
represent a small fraction (8 to 12%) of the patients' daily protein
intake, nevertheless, this is a loss that these patients can ill afford.
In addition, these data demonstrate an important link between
the dialysis membrane and protein catabolism.
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